Luminex Co. (NASDAQ:LMNX) – Investment analysts at Jefferies Group boosted their Q1 2018 earnings per share (EPS) estimates for shares of Luminex in a research report issued on Tuesday. Jefferies Group analyst B. Couillard now anticipates that the medical instruments supplier will post earnings of $0.18 per share for the quarter, up from their prior forecast of $0.17. Jefferies Group has a “Hold” rating and a $21.00 price objective on the stock. Jefferies Group also issued estimates for Luminex’s Q3 2018 earnings at $0.11 EPS, Q4 2018 earnings at $0.13 EPS, FY2018 earnings at $0.57 EPS and FY2019 earnings at $0.71 EPS.
Luminex (NASDAQ:LMNX) last released its quarterly earnings data on Monday, February 12th. The medical instruments supplier reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.11. Luminex had a net margin of 9.48% and a return on equity of 8.56%. The company had revenue of $78.20 million during the quarter, compared to analyst estimates of $77.33 million. During the same period last year, the business earned $0.11 earnings per share. Luminex’s revenue was up 8.2% compared to the same quarter last year.
Luminex (LMNX) opened at $19.60 on Wednesday. Luminex has a 1 year low of $17.68 and a 1 year high of $22.42. The company has a market cap of $850.69, a P/E ratio of 29.25, a PEG ratio of 1.84 and a beta of 0.13.
The business also recently announced a quarterly dividend, which will be paid on Friday, April 13th. Shareholders of record on Friday, March 23rd will be given a dividend of $0.06 per share. The ex-dividend date of this dividend is Thursday, March 22nd. This represents a $0.24 annualized dividend and a yield of 1.22%. Luminex’s payout ratio is presently 35.82%.
In other Luminex news, Director G Walter Loewenbaum II sold 39,456 shares of Luminex stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $20.40, for a total transaction of $804,902.40. Following the completion of the sale, the director now directly owns 651,736 shares in the company, valued at $13,295,414.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last quarter, insiders have sold 81,698 shares of company stock valued at $1,671,701. 6.90% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company lifted its position in Luminex by 1.3% during the second quarter. The Manufacturers Life Insurance Company now owns 31,640 shares of the medical instruments supplier’s stock valued at $668,000 after purchasing an additional 402 shares during the last quarter. New York State Common Retirement Fund lifted its position in Luminex by 1.4% during the second quarter. New York State Common Retirement Fund now owns 44,200 shares of the medical instruments supplier’s stock valued at $934,000 after purchasing an additional 599 shares during the last quarter. Voya Investment Management LLC lifted its position in Luminex by 1.9% during the second quarter. Voya Investment Management LLC now owns 92,553 shares of the medical instruments supplier’s stock valued at $1,955,000 after purchasing an additional 1,737 shares during the last quarter. Aperio Group LLC lifted its position in Luminex by 7.9% during the fourth quarter. Aperio Group LLC now owns 34,333 shares of the medical instruments supplier’s stock valued at $676,000 after purchasing an additional 2,521 shares during the last quarter. Finally, Legal & General Group Plc lifted its position in Luminex by 3.3% during the third quarter. Legal & General Group Plc now owns 78,767 shares of the medical instruments supplier’s stock valued at $1,602,000 after purchasing an additional 2,523 shares during the last quarter. Institutional investors and hedge funds own 76.64% of the company’s stock.
Luminex Company Profile
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.